公开(公告)号：US20240228082A1

公开(公告)日：2024-07-11

申请号：US18561759

申请日：2022-05-18

申请人： UCB BIOPHARMA SRL

发明人： SEBASTIEN DASNOY ,  LAURA SIMONIN

IPC分类号： B65B3/00 ,  G01F22/00

CPC分类号： B65B3/003 ,  G01F22/00

摘要： The invention relates to the pharmaceutical field and in particular to methods related to the filling of containers containing liquid-in-vial drug products.

公开(公告)号：US12018021B2

公开(公告)日：2024-06-25

申请号：US16973701

申请日：2019-06-20

申请人： UCB Biopharma SRL

发明人： Pfrafulkumar Tulshibhai Chovatia ,  Rickki Lee Connelly ,  Richard Jeremy Franklin ,  Gregory William Haslett ,  Alistair James Henry ,  James Madden ,  Judi Charlotte Neuss ,  Timothy John Norman ,  Oliver Philps ,  William Ross Pitt ,  Konstantinos Rampalakos ,  Matthew Duncan Selby ,  Selvaratnam Suganthan ,  Giancarlo Trani ,  Zhaoning Zhu

IPC分类号： C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

CPC分类号： C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

摘要： Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

公开(公告)号：US20240123065A1

公开(公告)日：2024-04-18

申请号：US18394323

申请日：2023-12-22

申请人： UCB BIOPHARMA SRL

发明人： Sandrine Durran ,  Andrew Jeffrey Yates

IPC分类号： A61K39/395 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C07K16/24

CPC分类号： A61K39/39591 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C07K16/244 ,  C07K2317/76

摘要： The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.

公开(公告)号：US20240083925A1

公开(公告)日：2024-03-14

申请号：US18267946

申请日：2021-12-16

申请人： UCB Biopharma SRL

发明人： Ali Ates ,  Celal Ates ,  Laurent Provins

IPC分类号： C07F9/6558 ,  C07D401/06

CPC分类号： C07F9/65583 ,  C07D401/06

摘要： The present invention relates to a prodrug of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone, which prodrug is represented by formula (II).

公开(公告)号：US20240067758A1

公开(公告)日：2024-02-29

申请号：US18255213

申请日：2021-12-06

申请人： UCB BIOPHARMA SRL

发明人： Joseph Michael David RASTRICK ,  John Paul SILVA ,  Daniel John LIGHTWOOD ,  Ralph ADAMS ,  Roger Thomas PALFRAMAN ,  Kerry Louise TYSON ,  Peter Charles ELLIOTT ,  Seema MAYANK ,  Andrea Julie CROSBY ,  Emily Mary Cairistine BARRY ,  Seppe Frans Roman LEYSEN ,  Zainab AHDASH

IPC分类号： C07K16/46 ,  C12N15/63 ,  A61P17/00

CPC分类号： C07K16/468 ,  C12N15/63 ,  A61P17/00 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2317/565 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/14

摘要： The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.

公开(公告)号：US20240043400A1

公开(公告)日：2024-02-08

申请号：US18265156

申请日：2021-12-01

申请人： UCB Biopharma SRL

发明人： Ali Ates ,  Pierre Burssens ,  Adrian Hall ,  Laurent Provins ,  David Skolc ,  Anne Valade

IPC分类号： C07D401/06 ,  C07D217/04 ,  C07D471/04 ,  C07D401/10

CPC分类号： C07D401/06 ,  C07D217/04 ,  C07D471/04 ,  C07D401/10

摘要： The present invention relates to octahydroisoquinolinyl derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.

公开(公告)号：US20230355758A1

公开(公告)日：2023-11-09

申请号：US18152872

申请日：2023-01-11

申请人： UCB BIOPHARMA SRL

发明人： Andrew Jeffrey Yates ,  James Gregory Clipstone

IPC分类号： A61K39/395 ,  C07K16/22 ,  A61K9/00 ,  A61K47/18 ,  A61K9/08 ,  A61K47/20 ,  A61K47/40

CPC分类号： A61K39/39591 ,  C07K16/22 ,  A61K9/0019 ,  A61K47/183 ,  A61K9/08 ,  A61K47/20 ,  A61K47/40 ,  C07K2317/24 ,  A61K2039/54

摘要： The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-bindmg fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis. Furthermore, the invention relates to a method of reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclo dextrin and methionine.

公开(公告)号：US20230277687A1

公开(公告)日：2023-09-07

申请号：US18006056

申请日：2021-08-06

申请人： Fundacion Para La Investigacion Medica Aplicada ,  CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DEL ÁREA DE ENFERMEDADES NEURODEGENERATIVAS M.P C ,  UCB BIOPHARMA SRL

发明人： Gloria GONZÁLEZ-ASEGUINOLAZA ,  Diego SUCUNZA GUIBERT ,  José Luis LANCIEGO PÉREZ ,  Ralph Michael LINDEN

IPC分类号： A61K48/00 ,  C12N9/24 ,  C12N15/86 ,  A61K38/47 ,  A61K49/00 ,  A61P25/28

CPC分类号： A61K48/0058 ,  C12N9/2402 ,  C12Y302/01045 ,  C12N15/86 ,  A61K38/47 ,  A61K48/0041 ,  A61K49/0004 ,  A61P25/28 ,  C12N2750/14143 ,  C12N2750/14171

摘要： The present disclosure relates to viral particles for use in treating tauopathies, particularly Alzheimer's disease, by gene therapy. More specifically, the present invention relates to a viral particle for use in treating tauopathies by gene therapy in a subject in need thereof, said viral particle comprising a nucleic acid construct including a transgene encoding a glucocerebro sidase.

公开(公告)号：US20230250105A1

公开(公告)日：2023-08-10

申请号：US18175030

申请日：2023-02-27

申请人： UCB Biopharma SRL ,  SANOFI

发明人： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC分类号： C07D487/18

CPC分类号： C07D487/18 ,  C07B2200/05

摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20230192646A1

公开(公告)日：2023-06-22

申请号：US17786300

申请日：2020-12-22

申请人： UCB Biopharma SRL

发明人： Timothy John NORMAN ,  Jag Paul HEER ,  Oliver PHILPS ,  William Ross PITT ,  James MADDEN ,  Zeshan YOUSUF

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D215/06

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D215/06

摘要： The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.